drugset
drugset / Trial / NCT01261247

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT01261247 ↗

Phase 2 Completed 41 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma

Timeline

Start
2011-01-17
Primary completion
2016-05-09
Completion
2019-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule — Oral

Indications

Burkitt lymphoma MALT lymphoma Waldenstrom macroglobulinemia adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma extranodal nasal NK/T cell lymphoma hepatosplenic T-cell lymphoma lymphoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma peripheral T-cell lymphoma, not otherwise specified post-transplant lymphoproliferative disease small intestine lymphoma splenic marginal zone lymphoma